Journal issues > Issue 4, August 2018 > Highlights in myelodysplastic syndromes and myeloproliferative neoplasms

Highlights in myelodysplastic syndromes and myeloproliferative neoplasms

SUMMARY

Novel therapeutic options for patients suffering from myelodysplastic syndromes (MDS) have not managed to climb the stage in recent years. However, clinical trials with new agents were ongoing under the radar. During the 2018 annual EHA meeting, new results were presented that may be inspiring for new clinical trials leading to drug approvals and the expansion of our therapeutic arsenal in this difficult-to-treat patient population. In addition to MDS, this overview will also address the key data on myeloproliferative diseases presented at EHA 2018.

(BELG J HEMATOL 2018;9(4):157–60)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top